Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9685552 | 0.85 | CHRNE (0.37) | PLAUESR2MAP2K1ALDH1A1KDM4E | |
| SCHEMBL6457244 | 0.81 | AR (0.39) | PLAUMAP2K1ALDH1A1KDM4ECYP1A2 | |
| SCHEMBL30129807 | 0.80 | FFAR1 (0.44) | ESR2ALDH1A1FFAR1KDM4EKMT2A | |
| SCHEMBL536176 | 0.80 | FFAR1 (0.44) | ESR2ALDH1A1FFAR1KDM4EKMT2A | |
| SCHEMBL9686928 | 0.79 | TLR8 (0.41) | ALDH1A1KMT2ATSHRMAPTSMN1; SMN2 | |
| SCHEMBL26463373 | 0.79 | PNMT (0.39) | PLAUMAP2K1ALDH1A1KDM4ECYP1A2 | |
| SCHEMBL29278135 | 0.78 | NOTUM (0.35) | ESR2ALDH1A1FFAR1KMT2AHTR2A | |
| SCHEMBL4247247 | 0.77 | TLR8 (0.42) | TSHR | |
| SCHEMBL7863918 | 0.77 | GABRA1 (0.40) | PLAUMAP2K1ALDH1A1KDM4ECYP1A2 | |
| SCHEMBL10798754 | 0.77 | PLAU (0.36) | PLAUMAP2K1ALDH1A1KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122892-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-8129403-B2 | e.g. 2-[9-(5-Cyclopropyl-1H-pyrazol-3-yl)-6-methyl-9H-purin-2-ylamino]-2-(4-fluorophenyl)ethanol; tropomyosin-related kinases (Trk's) inhibitor; anticarcinoganic agent; solid tumors and leukemia | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| US-20090227648-A1 | PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | ASTRAZENECA AB | 2009-09-10 | — | — | US | disclosed |
| US-20080176872-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176872-A1 | Chemical Compounds | TP53, XPOT, KRAS | PLAU 3607/4885ESR2 520/4885MAP2K1 4702/4885 |
| US-20120122892-A1 | CHEMICAL COMPOUNDS | TP53, XPOT, KRAS | PLAU 3653/4885ESR2 419/4885MAP2K1 4695/4885 |
| US-20090227648-A1 | PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | TP53, PDK2, PDK1 | PLAU 3050/4885ESR2 1678/4885MAP2K1 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.